View source for GLP-1 receptor agonist

== Problems ==

* '''Type 2 diabetes mellitus''', first- or second-line per [[ADA Standards of Care|ADA 2025 Standards of Care]],<ref name="ada2025">American Diabetes Association. ''Standards of Care in Diabetes, 2025.'' ''Diabetes Care'' 48(Suppl. 1):S1–S352. doi:10.2337/dc25-S001</ref> especially when [[ASCVD]], [[heart failure]], [[CKD]], or obesity is co-present
* '''Obesity or overweight with weight-related comorbidity''', BMI ≥30, or ≥27 with a weight-related condition (semaglutide 2.4 mg,<ref name="wegovy-label">US FDA. ''Wegovy (semaglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf</ref> tirzepatide,<ref name="zepbound-label">US FDA. ''Zepbound (tirzepatide) prescribing information.'' Eli Lilly. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf</ref> liraglutide 3 mg<ref name="saxenda-label">US FDA. ''Saxenda (liraglutide) prescribing information.'' Novo Nordisk. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf</ref>)
* '''Cardiovascular risk reduction in obesity without T2DM''', semaglutide 2.4 mg (SELECT)<ref name="select"/>
* '''MASH with stage 2–3 fibrosis''', semaglutide (FDA 2025, based on ESSENCE)<ref name="essence"/>
* '''CKD in T2DM''', semaglutide adjunctive label (FLOW)<ref name="flow"/>